Logo image of NEPH

NEPHROS INC (NEPH) Stock Fundamental Analysis

NASDAQ:NEPH - Nasdaq - US6406714005 - Common Stock - Currency: USD

3.88  +0.07 (+1.84%)

Fundamental Rating

4

Taking everything into account, NEPH scores 4 out of 10 in our fundamental rating. NEPH was compared to 128 industry peers in the Machinery industry. No worries on liquidiy or solvency for NEPH as it has an excellent financial health rating, but there are worries on the profitability. NEPH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

In the past year NEPH was profitable.
In the past year NEPH had a positive cash flow from operations.
In the past 5 years NEPH reported 4 times negative net income.
In the past 5 years NEPH reported 4 times negative operating cash flow.
NEPH Yearly Net Income VS EBIT VS OCF VS FCFNEPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M

1.2 Ratios

NEPH's Return On Assets of 6.80% is fine compared to the rest of the industry. NEPH outperforms 65.63% of its industry peers.
NEPH has a Return On Equity (8.62%) which is in line with its industry peers.
NEPH has a Return On Invested Capital (6.26%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA 6.8%
ROE 8.62%
ROIC 6.26%
ROA(3y)-26.57%
ROA(5y)-25.75%
ROE(3y)-50%
ROE(5y)-44.65%
ROIC(3y)N/A
ROIC(5y)N/A
NEPH Yearly ROA, ROE, ROICNEPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

NEPH has a Profit Margin (5.16%) which is in line with its industry peers.
NEPH has a worse Operating Margin (4.98%) than 62.50% of its industry peers.
With an excellent Gross Margin value of 62.45%, NEPH belongs to the best of the industry, outperforming 97.66% of the companies in the same industry.
NEPH's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.98%
PM (TTM) 5.16%
GM 62.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.79%
GM growth 5Y0.91%
NEPH Yearly Profit, Operating, Gross MarginsNEPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NEPH is destroying value.
Compared to 1 year ago, NEPH has about the same amount of shares outstanding.
Compared to 5 years ago, NEPH has more shares outstanding
Compared to 1 year ago, NEPH has a worse debt to assets ratio.
NEPH Yearly Shares OutstandingNEPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
NEPH Yearly Total Debt VS Total AssetsNEPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -4.87, we must say that NEPH is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.87, NEPH is not doing good in the industry: 91.41% of the companies in the same industry are doing better.
NEPH has a debt to FCF ratio of 0.05. This is a very positive value and a sign of high solvency as it would only need 0.05 years to pay back of all of its debts.
NEPH's Debt to FCF ratio of 0.05 is amongst the best of the industry. NEPH outperforms 92.19% of its industry peers.
NEPH has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, NEPH belongs to the top of the industry, outperforming 83.59% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Altman-Z -4.87
ROIC/WACC0.63
WACC9.97%
NEPH Yearly LT Debt VS Equity VS FCFNEPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

NEPH has a Current Ratio of 5.92. This indicates that NEPH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.92, NEPH belongs to the top of the industry, outperforming 94.53% of the companies in the same industry.
NEPH has a Quick Ratio of 4.64. This indicates that NEPH is financially healthy and has no problem in meeting its short term obligations.
NEPH has a Quick ratio of 4.64. This is amongst the best in the industry. NEPH outperforms 94.53% of its industry peers.
Industry RankSector Rank
Current Ratio 5.92
Quick Ratio 4.64
NEPH Yearly Current Assets VS Current LiabilitesNEPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

6

3. Growth

3.1 Past

NEPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 150.00%, which is quite impressive.
NEPH shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.32%.
The Revenue has been growing slightly by 6.51% on average over the past years.
EPS 1Y (TTM)150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%350%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y11.49%
Revenue growth 5Y6.51%
Sales Q2Q%38.47%

3.2 Future

Based on estimates for the next years, NEPH will show a very strong growth in Earnings Per Share. The EPS will grow by 10844260754.01% on average per year.
NEPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.70% yearly.
EPS Next Y587989967349491800%
EPS Next 2Y10844260754.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year17.25%
Revenue Next 2Y14.7%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NEPH Yearly Revenue VS EstimatesNEPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
NEPH Yearly EPS VS EstimatesNEPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.2 -0.4 -0.6

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 55.43, NEPH can be considered very expensive at the moment.
Based on the Price/Earnings ratio, NEPH is valued a bit more expensive than the industry average as 69.53% of the companies are valued more cheaply.
When comparing the Price/Earnings ratio of NEPH to the average of the S&P500 Index (26.59), we can say NEPH is valued expensively.
NEPH is valuated quite expensively with a Price/Forward Earnings ratio of 95.10.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NEPH indicates a slightly more expensive valuation: NEPH is more expensive than 71.09% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.39, NEPH is valued quite expensively.
Industry RankSector Rank
PE 55.43
Fwd PE 95.1
NEPH Price Earnings VS Forward Price EarningsNEPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NEPH is valued a bit more expensive than the industry average as 75.00% of the companies are valued more cheaply.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NEPH indicates a slightly more expensive valuation: NEPH is more expensive than 69.53% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 92.01
EV/EBITDA 40.51
NEPH Per share dataNEPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1

4.3 Compensation for Growth

NEPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NEPH's earnings are expected to grow with 10844260754.01% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y10844260754.01%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for NEPH!.
Industry RankSector Rank
Dividend Yield N/A

NEPHROS INC

NASDAQ:NEPH (6/10/2025, 8:00:01 PM)

3.88

+0.07 (+1.84%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06
Inst Owners44.7%
Inst Owner Change-0.99%
Ins Owners11.86%
Ins Owner Change2.61%
Market Cap41.13M
Analysts82.5
Price Target4.85 (25%)
Short Float %0.03%
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)688.24%
Min EPS beat(2)296.08%
Max EPS beat(2)1080.39%
EPS beat(4)3
Avg EPS beat(4)369.61%
Min EPS beat(4)-96.08%
Max EPS beat(4)1080.39%
EPS beat(8)6
Avg EPS beat(8)186.58%
EPS beat(12)7
Avg EPS beat(12)103.11%
EPS beat(16)8
Avg EPS beat(16)71.4%
Revenue beat(2)2
Avg Revenue beat(2)18.61%
Min Revenue beat(2)6.29%
Max Revenue beat(2)30.93%
Revenue beat(4)2
Avg Revenue beat(4)4.59%
Min Revenue beat(4)-17.42%
Max Revenue beat(4)30.93%
Revenue beat(8)4
Avg Revenue beat(8)1.96%
Revenue beat(12)5
Avg Revenue beat(12)-0.04%
Revenue beat(16)5
Avg Revenue beat(16)-3.1%
PT rev (1m)5.56%
PT rev (3m)-5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)1.39%
Revenue NQ rev (3m)-1.38%
Revenue NY rev (1m)7.17%
Revenue NY rev (3m)7.44%
Valuation
Industry RankSector Rank
PE 55.43
Fwd PE 95.1
P/S 2.65
P/FCF 92.01
P/OCF 81.93
P/B 4.43
P/tB 5.15
EV/EBITDA 40.51
EPS(TTM)0.07
EY1.8%
EPS(NY)0.04
Fwd EY1.05%
FCF(TTM)0.04
FCFY1.09%
OCF(TTM)0.05
OCFY1.22%
SpS1.46
BVpS0.88
TBVpS0.75
PEG (NY)0
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.8%
ROE 8.62%
ROCE 7.52%
ROIC 6.26%
ROICexc 10.39%
ROICexgc 13.16%
OM 4.98%
PM (TTM) 5.16%
GM 62.45%
FCFM 2.88%
ROA(3y)-26.57%
ROA(5y)-25.75%
ROE(3y)-50%
ROE(5y)-44.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.79%
GM growth 5Y0.91%
F-Score6
Asset Turnover1.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Debt/EBITDA 0.02
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 772
Cash Conversion 54.86%
Profit Quality 55.81%
Current Ratio 5.92
Quick Ratio 4.64
Altman-Z -4.87
F-Score6
WACC9.97%
ROIC/WACC0.63
Cap/Depr(3y)38.4%
Cap/Depr(5y)49.1%
Cap/Sales(3y)0.77%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%350%
EPS Next Y587989967349491800%
EPS Next 2Y10844260754.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.32%
Revenue growth 3Y11.49%
Revenue growth 5Y6.51%
Sales Q2Q%38.47%
Revenue Next Year17.25%
Revenue Next 2Y14.7%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y151.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y135.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.65%
OCF growth 3YN/A
OCF growth 5YN/A